Abstract
CEP-1347 is a potent inhibitor of mixed lineage kinase (MLK), which was investigated for ameliorating HIV-associated neurocognitive disorders. CEP-1347 and atazanavir pharmacokinetics were determined when CEP-1347 50 mg twice daily was administered to HIV-infected patients (n = 20) receiving combination antiretroviral therapy including atazanavir and ritonavir (ATV/RTV, 300/100 mg) once daily continuously. Co-administration of CEP-1347 and ATV/RTV resulted with significant changes in pharmacokinetics of ATV but not RTV. Specifically, an increase in ATV accumulation ratio of 15 % (p = 0.007) and a prolongation of T(½) from 12.7 to 15.9 h (p = 0.002) were observed. The results suggested that co-administration of CEP-1347 with ATV/RTV in HIV-infected patients might result in limited impact on ATV but not on RTV pharmacokinetics.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Anti-HIV Agents / administration & dosage
-
Anti-HIV Agents / blood
-
Anti-HIV Agents / pharmacokinetics*
-
Atazanavir Sulfate
-
CD4 Lymphocyte Count
-
Carbazoles / administration & dosage
-
Carbazoles / blood
-
Carbazoles / pharmacokinetics*
-
Drug Administration Schedule
-
Drug Interactions
-
Drug Therapy, Combination
-
HIV Infections / drug therapy*
-
HIV Infections / virology
-
HIV-1 / drug effects
-
HIV-1 / growth & development
-
Half-Life
-
Humans
-
MAP Kinase Kinase Kinases / antagonists & inhibitors
-
MAP Kinase Kinase Kinases / metabolism
-
Male
-
Middle Aged
-
Nootropic Agents / administration & dosage
-
Nootropic Agents / blood
-
Nootropic Agents / pharmacokinetics*
-
Oligopeptides / administration & dosage
-
Oligopeptides / blood
-
Oligopeptides / pharmacokinetics*
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / blood
-
Protein Kinase Inhibitors / pharmacokinetics*
-
Pyridines / administration & dosage
-
Pyridines / blood
-
Pyridines / pharmacokinetics*
-
Ritonavir / administration & dosage
-
Ritonavir / blood
-
Ritonavir / pharmacokinetics*
Substances
-
Anti-HIV Agents
-
Carbazoles
-
Nootropic Agents
-
Oligopeptides
-
Protein Kinase Inhibitors
-
Pyridines
-
3,9-bis((ethylthio)methyl)-K-252a
-
Atazanavir Sulfate
-
MAP Kinase Kinase Kinases
-
Ritonavir